Download PDF
Thromb Haemost 1997; 78(01): 161-172
DOI: 10.1055/s-0038-1657520
Molecular defects in rare bleeding disorders
Schattauer GmbH Stuttgart

Inherited Factor X Deficiency: Molecular Genetics and Pathophysiology

David N Cooper
1   institute of Medical Genetics, University of Wales College of Medicine, Cardiff, UK
,
David S Millar
1   institute of Medical Genetics, University of Wales College of Medicine, Cardiff, UK
,
Adam Wacey
2   Thrombosis Research Institute, London, UK
,
Susan Pemberton
3   Haemostasis Research Group, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK
,
Edward G D Tuddenham
3   Haemostasis Research Group, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Mammen EF. Factor X abnormalities. Sem Thromb Haemost 1983; 9: 31-44
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Girolami A. Tentative and updated classification of factor X variants. Acta Haemato 1986; 75: 58-59
    PubMedGoogle Scholar
  • 3 Denson KWE. Abnormal forms of factor X. Lancet 1969; 2: 1256
    PubMedGoogle Scholar
  • 4 Fair DS, Edgington TS. Heterogeneity of hereditary and acquired factor X deficiencies by combined immunochemical and functional analyses. Br J Haematol 1985; 59: 235-248
    CrossrefPubMedGoogle Scholar
  • 5 Giddings JC. Coagulation factor synthesis by the liver with special reference to factors V and VIII. In Fondu P, and Thijs O. (eds) Hemostatic Failure in Liver Disease. Martinus Nijhoff Boston. 1984. pp. 05-21
    Google Scholar
  • 6 Graves CB, Munns TW, Willingham AK, Stauss AW. Rat factor X is synthesized as a single chain precursor inducible by prothrombin fragments. J Biol Chem 1982; 257: 13108-13113
    PubMedGoogle Scholar
  • 7 Fair DS, Bahnak BR. Human hepatoma cells secrete single chain factor X, prothrombin and antithrombin III. Blood 1984; 64: 194-204
    PubMedGoogle Scholar
  • 8 Fair DS, Plow EF, Edgington TS. Combined functional and immunochemical analysis of normal and abnormal human factor X. J Clin Invest 1979; 64: 884-894
    CrossrefPubMedGoogle Scholar
  • 9 Henkens CM, Bom VJ, Van der Schaaf W, Pelsma PM, Sibinga CT, de Kam PJ, Van der Meer J. Plasma levels of protein S, protein C and factor X:effects of sex, hormonal state and age. Thromb Haemost 1995; 74: 1271-1275
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Stanton C, Wallin R. Processing and trafficking of clotting factor X in the secretory pathway. Effects of warfarin. Biochem J 1992; 284: 25-31
    CrossrefPubMedGoogle Scholar
  • 11 Fujikawa K, Titani K, Davie EW. Activation of bovine factor X (Stuart factor): conversion of activation of factor Xaa to Xab. Proc Natl Acad Sci USA 1975; 72: 3359-3363
    CrossrefPubMedGoogle Scholar
  • 12 Altieri DC. Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa. J Biol Chem 1994; 269: 3139-3142
    PubMedGoogle Scholar
  • 13 Altieri DC. Xa receptor EPR-1. FASEB J 1995; 9: 860-865
    CrossrefPubMedGoogle Scholar
  • 14 Ambrosini G, Altieri DC. Molecular dissection of effector cell protease receptor-1 recognition of factor Xa. Assignment of critical residues involved in antibody reactivity and ligand binding. J Biol Chem 1996; 271: 1243-1248
    CrossrefPubMedGoogle Scholar
  • 15 Gajdusek C, Carbon S, Ross R, Nawroth P, Stem D. Activation of coagulation releases endothelial cell mitogens. J Cell Biol 1986; 103: 419-428
    CrossrefPubMedGoogle Scholar
  • 16 Gasic GP, Arenas CP, Gasic TB, Gasic GJ. Coagulation factors X, Xa and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci USA 1992; 89: 2317-2320
    CrossrefPubMedGoogle Scholar
  • 17 Nicholson AC, Nachman RL, Altieri DC, Summers BD, Ruf W, Edgington TS, Hajjar DP. Effector cell protease receptor-1 is a vascular receptor for coagulation factor Xa. J Biol Chem 1996; 271: 28407-2813
    CrossrefPubMedGoogle Scholar
  • 18 Padmanabhan K, Padmanabhan KP, Tulinsky A, Park CH, Bode W, Huber R, Blankenship DT, Cardin AD, Kisiel W. Structure of human des(l-45) factor Xa at 2.2A resolution. J Mol Biol 1993; 232: 947-966
    CrossrefPubMedGoogle Scholar
  • 19 Rezaie AR, Esmon CT. Asp70→Lys mutant of factor X lacks high affinity Ca2+ binding site yet retains function. J Biol Chem 1994; 269: 21495-21499
    PubMedGoogle Scholar
  • 20 Sunnerhagen M, Forsen S, Hoffren A-M, Drakenberg T, Teleman O, Stenflo J. Structure of the Ca2+-free GLA domain sheds light on membrane binding of blood coagulation proteins. Nature Struct Biol 1995; 2: 504-509
    CrossrefPubMedGoogle Scholar
  • 21 Scandura JM, Ahmad SS, Walsh PN. A binding site on the surface of activated human platelets is shared by factor X and prothrombin. Biochemistry 1996; 35: 8890-8902
    CrossrefPubMedGoogle Scholar
  • 22 Hoffman M, Monroe DM, Roberts HR. Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia. Blood 1994; 83: 38-42
    PubMedGoogle Scholar
  • 23 Brinkman H-JM, Mertens K, Holthuis J, Zwart-Huinink LA, Grijm K, Van Mourik JA. The activation of human blood coagulation factor X on the surface of endothelial cells: a comparison with various vascular cells, platelets and monocytes. Brit J Haematol 1994; 87: 332-342
    CrossrefPubMedGoogle Scholar
  • 24 Ahmad SS, Rawala-Sheikh R, Walsh P. Platelet receptor occupancy with factor IXa promotes factor X activation. J Biol Chem 1989; 264: 20012-20016
    PubMedGoogle Scholar
  • 25 van Diejen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and FVIIIa in the activation of bovine factor X. J Biol Chem 1981; 256: 3433-3442
    PubMedGoogle Scholar
  • 26 ten Cate H, Bauer KA, Levi M, Edgington TS, Sublett RD, Barzegar S, Kass BL, Rosenberg RD. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993; 92: 1207-1212
    CrossrefPubMedGoogle Scholar
  • 27 Huang Q, Neuenschwander PF, Rezaie AR, Morrissey JH. Substrate recognition by tissue factor-factor VIIa. J Biol Chem 1996; 271: 21752-21757
    CrossrefPubMedGoogle Scholar
  • 28 Komiyama Y, Pedersen AH, Kisiel W. Proteolytic activation of human factors IX and X by recombinant human factor VIIa: Effects of calcium, phospholipids and tissue factor. Biochemistry 1990; 29: 9418-9425
    CrossrefPubMedGoogle Scholar
  • 29 Tucker MM, Foster WB, Katzmann JA, Mann KG. A monoclonal antibody which inhibits the factor Va:factor Xa interaction. J Biol Chem 1983; 258: 1210-1214
    PubMedGoogle Scholar
  • 30 Annamalai AE, Rao RK, Chin HCC. et al Epitope mapping of functional domains of human factor V with murine monoclonal antibodies. Blood 1987; 70: 139-146
    PubMedGoogle Scholar
  • 31 Skogen WF, Esmon CT, Cox AC. Comparison of coagulation factor Xa and des-(l-44) factor Xa in the assembly of prothrombinase. J Biol Chem 1984; 259: 2306-2310
    PubMedGoogle Scholar
  • 32 Persson E, Valcarce C, Stenflo J. The γ-carboxyglutamic acid and epidermal growth factor-like domains of factor X. J Biol Chem 1991; 266: 2453-2458
    PubMedGoogle Scholar
  • 33 Ye J, Esmon CT. Factor Xa-factor Va complex assembles in two dimensions with unexpectedly high affinity: an experimental and theoretical analysis. Biochemistry 1995; 34: 6448-6453
    CrossrefPubMedGoogle Scholar
  • 34 Nicolaes GAF, Tans G, Thomassen CLGD, Hemker HC, Pabinger I, Varadi K, Schwarz HP, Rosing J. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270: 21158-21166
    CrossrefPubMedGoogle Scholar
  • 35 Hertzberg MS, Ben-Tal O, Furie B, Furie BC. Construction, expression and characterization of a chimera of factor IX and factor X. J Biol Chem 1992; 267: 14759-14766
    PubMedGoogle Scholar
  • 36 Chattopadhyay A, James HL, Fair DS. Molecular recognition sites on factor Xa which participate in the prothrombinase complex. J Biol Chem 1992; 267: 12323-12329
    PubMedGoogle Scholar
  • 37 Iino M, Takeya H, Takemitsu T, Nakagaki T, Gabazza EC, Suzuki K. Characterization of the binding of factor Xa to fibrinogen/fibrin derivatives and localization of the factor Xa binding site on fibrinogen. Eur J Biochem 1995; 232: 90-97
    CrossrefPubMedGoogle Scholar
  • 38 Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993; 91: 1877-1883
    CrossrefPubMedGoogle Scholar
  • 39 Pryzdial ELG, Bajzar L, Nesheim ME. Prothrombinase components can accelerate tissue plasminogen activator-catalyzed plasminogen activation. J Biol Chem 1995; 270: 17871-17877
    CrossrefPubMedGoogle Scholar
  • 40 Pryzdial ELG, Kessler GE. Autoproteolysis or plasmin-mediated cleavage of factor Xaa exposes a plasminogen binding site and inhibits coagulation. J Biol Chem 1996; 271: 16614-16620
    CrossrefPubMedGoogle Scholar
  • 41 Pryzdial ELG, Kessler GE. Kinetics of blood coagulation factor Xaα autoproteolytic conversion to factor Xaβ. J Biol Chem 1996; 271: 16621-16626
    CrossrefPubMedGoogle Scholar
  • 42 Huang Z-F, Wun T-C, Broze GJ. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 1993; 268: 26950-26955
    PubMedGoogle Scholar
  • 43 Lindhout T, Willems G, Blezer R, Hemker HC. Kinetics of the inhibition of human factor Xa by full-length and truncated recombinant tissue factor pathway inhibitor. Biochem J 1994; 297: 131-136
    CrossrefPubMedGoogle Scholar
  • 44 Broze GJ. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46: 103-112
    CrossrefPubMedGoogle Scholar
  • 45 Ho G, Toomey JR, Broze GJ, Schwartz AL. Receptor-mediated endocytosis of coagulation factor Xa requires cell surface-bound tissue factor pathway inhibitor. J Biol Chem 1996; 271: 9497-9502
    CrossrefPubMedGoogle Scholar
  • 46 Gitel SN, Medina VM, Wessler S. Inhibition of human activated factor X by antithrombin III and α-proteinase inhibitor in human plasma. J Biol Chem 1984; 259: 6890-6895
    PubMedGoogle Scholar
  • 47 Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993; 91: 1877-1883
    CrossrefPubMedGoogle Scholar
  • 48 Barrow RT, Parker ET, Krishnaswamy S, Lollar P. Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator. J Biol Chem 1994; 269: 26796-2800
    PubMedGoogle Scholar
  • 49 Solymoss S, Tucker MM, Tracy PB. Kinetics of inactivation of membrane bound factor Va by activated protein C. Protein S modulates factor Xa ptotection. J Biol Chem 1988; 263: 14884-14890
    PubMedGoogle Scholar
  • 50 Heeb MJ, Rosing J, Bakker HM, Fernandez JA, Tans G, Griffin JH. Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci USA 1994; 91: 2728-2732
    CrossrefPubMedGoogle Scholar
  • 51 Koppelman SJ, Hackeng TM, Sixma JJ, Bouma BN. Inhibition of the intrinsic factor X activating complex by protein S: evidence for a specific binding of protein S to factor VIII. Blood 1995; 86: 1062-1071
    PubMedGoogle Scholar
  • 52 Koppelman SJ, van’t Veer C, Sixma JJ, Bouma BN. Synergistic inhibition of the intrinsic factor X activation activation by protein S and C4b-binding protein. Blood 1995; 86: 2653-2660
    PubMedGoogle Scholar
  • 53 Hackeng TM, van’t Veer C, Meijers JCM, Bouma BN. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem 1994; 269: 21051-21058
    PubMedGoogle Scholar
  • 54 Leytus SP, Foster DC, Kurachi K, Davie EW. Gene for human factor X: A blood coagulation factor whose gene organization is essentially identical with that of factor IX and protein C. Biochemistry 1986; 25: 5098-5102
    CrossrefPubMedGoogle Scholar
  • 55 Messier TL, Pittman DD, Long GL, Kaufman RJ, Church WR. Cloning and expression in COS-1 cells of a full-length cDNA encoding human coagulation factor X. Gene 1991; 99: 291-294
    CrossrefPubMedGoogle Scholar
  • 56 Fung MR, Campbell RM, MacGillivray RTA. Blood coagulation factor X mRNA encodes a single polypeptide chain containing a prepro leader sequence. Nucleic Acids Res 1984; 12: 4481-4492
    CrossrefPubMedGoogle Scholar
  • 57 Murakawa M, Okamuia T, Kamura T, Kuroiwa M, Harada M, Niho Y. Analysis of the partial nucleotide sequences and deduced primary structures of the protease domains of mammalian blood coagulation factors VII and X. Eur J Haematol 1994; 52: 162-168
    PubMedGoogle Scholar
  • 58 Stanton C, Ross RP, Hutson S, Wallin R. Processing and expression of rat and human clotting factor X-encoding cDNAs. Gene 1996; 169: 269-273
    CrossrefPubMedGoogle Scholar
  • 59 Jagadeeswaran P, Reddy SK, Rao KJ, Hamsabhushanam K, Lyman G. Cloning and characterization of the 5’ end (exon 1) of the gene encoding human factor X. Gene 1989; 84: 517-519
    CrossrefPubMedGoogle Scholar
  • 60 Krawczak M, Wacey A, Cooper DN. Molecular reconstruction and homology modelling of the catalytic domain of the common ancestor of the haemostatic vitamin K-dependent serine proteinases. Hum Genet 1996; 98: 351-370
    CrossrefPubMedGoogle Scholar
  • 61 Jaye M, Ricca G, Kaplan R, Howk R, Mudd R, Ngo KY, Fair DS, Drohan W. Polymorphism associated with the coagulation factor X gene. Nucleic Acids Res 1985; 13: 8286
    CrossrefPubMedGoogle Scholar
  • 62 Hassan HJ, Guerriero R, Chelucci C, Leonardi A, Mattia G, Leone G, Mariani G, Mannucci PM, Peschle C. Multiple polymorphism sites in factor X locus. Blood 1988; 71: 1353-1356
    PubMedGoogle Scholar
  • 63 Hay CW, Robertson KA, Fung MR, MacGillivray RTA. RFLPs for Pstl and EcoRl in the human blood clotting factor X gene. Nucleic Acids Res 1986; 14: 5118
    CrossrefPubMedGoogle Scholar
  • 64 Wallmark A, Rose VL, Ho C, High KA. A NlalV polymorphism within the human factor X gene. Nucleic Acids Res 1991; 19: 4022
    PubMedGoogle Scholar
  • 65 Scambler PJ, Williamson R. The structural gene for human coagulation factor X is located on chromosome 13q34. Cytogenet. Cell Genet 1985; 39: 231-233
    CrossrefPubMedGoogle Scholar
  • 66 Rocchi M, Roncuzzi L, Santamaria R, Archidiacono N, Dente L, Romeo G. Mapping through somatic cell hybrids and cDNA probes of protein C to chromosome 2, factor X to chromosome 13 and αl-acid glycoprotein to chromosome 9. Hum Genet 1986; 74: 30-33
    PubMedGoogle Scholar
  • 67 Royle NJ, Fung MR, MacGillivray RTA, Hamerton JL. The gene for clotting factor 10 is mapped to 13q32-qter. Cytogenet. Cell Genet 1986; 41: 185-188
    CrossrefPubMedGoogle Scholar
  • 68 Miao CH, Leytus SP, Chung DW, Davie EW. Liver-specific expression of the gene coding for human factorX, a blood coagulation factor. J Biol Chem 1992; 267: 7395-7401
    PubMedGoogle Scholar
  • 69 Bahnak BR, Howk R, Morrissey JH, Ricca GA, Edgington TS, Jaye MC, Drohan WW, Fair DS. Steady state levels of factor X mRNA in liver and HepG2 cells. Blood 1987; 69: 224-230
    PubMedGoogle Scholar
  • 70 Hung HL, High KA. Liver-enriched transcription factor HNF-4 and ubiquitous factor NF-Y are critical for expression of blood coagulation factor X. J Biol Chem 1996; 271: 2323-2331
    CrossrefPubMedGoogle Scholar
  • 71 Leytus SP, Chung DW, Kisiel W, Kurachi K, Davie EW. Characterization of a cDNA coding for human factor X. Proc Natl Acad Sci USA 1984; 81: 3699-3702
    CrossrefPubMedGoogle Scholar
  • 72 Fung MR, Hay CW, MacGillivray RTA. Characterization of an almost full-length cDNA coding for human blood coagulation factor X. Proc Natl Acad Sci USA 1985; 82: 3591-3595
    CrossrefPubMedGoogle Scholar
  • 73 Huang M-N, High KA. Functional characterization of the 5’ regulatory region of the human factor X gene. Thromb Haemost 1991; 65: 726
    PubMedGoogle Scholar
  • 74 Huang M-N, Hung H-L, Stanfield-Oakley SA, High KA. Characterization of the human blood coagulation factor X promoter. J Biol Chem 1992; 267: 15440-15446
    PubMedGoogle Scholar
  • 75 Telfer TP, Denson KW, Wright DR. A ’new’ coagulation defect. Br J Haematol 1956; 2: 308-316
    CrossrefPubMedGoogle Scholar
  • 76 Hougie C, Barrow HM, Graham JB. Stuart clotting defect. Segregation of a hereditary hemorrhagic state from the heterozygous heretofore called ‘stable factor’ (SPCA, proconvertin factor VII deficiency). J Clin Invest 1957; 36: 485-493
    CrossrefPubMedGoogle Scholar
  • 77 Fair DS, Plow EF, Edgington TS. Combined functional and immunochemical analysis of normal and abnormal human factor X. J Clin Invest 1979; 64: 884-894
    CrossrefPubMedGoogle Scholar
  • 78 Bemardi F, Marchetti G, Patracchini P, Volinia S, Gemmati D, Simioni P, Girolami A. Partial gene deletion in a family with factor X deficiency. Blood 1989; 73: 2123-2127
    PubMedGoogle Scholar
  • 79 Wieland K, Millar DS, Grundy CB, Mibashan RS, Kakkar VV, Cooper DN. Molecular genetic analysis of factor X deficiency :gene deletion and germline mosaicism. Hum Genet 1991; 86: 273-278
    PubMedGoogle Scholar
  • 80 Reddy SV, Zhou Z-Q, Rao KJ, Scott JP, Watzke H, High KA, Jagadeeswaran P. Molecular characterization of human factor XsanAntonio . Blood 1989; 74: 1486-1490
    PubMedGoogle Scholar
  • 81 Girolami A, Molaro G, Lazzarin M, Brunetti A, Scarpa R. A new congenital haemonhagie condition due to the presence of an abnormal factor X (Factor X Friuli). Study of a large kindred. Br J Haematol 1970; 19: 179-192
    CrossrefPubMedGoogle Scholar
  • 82 Girolami A, Sticchi A, Brunetti A. Prothrombin level and activity in the abnormal factor X (Factor X Friuli) hemorrhagic disorder. Thromb Diath Haemhorrag 1971; 25: 147-156
    PubMedGoogle Scholar
  • 83 Girolami A, Molaro G, Falomo R. Factor X Friuli coagulation disorder. Acta Haematol 1975; 54: 120-125
    CrossrefPubMedGoogle Scholar
  • 84 Girolami A, Lazzarin M, Procidano M, Luzzatto G. A family with heterozygous factor X Friuli defect outside Friuli. Blut 1983; 46: 149-155
    CrossrefPubMedGoogle Scholar
  • 85 Fair D, Revak D, Edgington T, Girolami A. Structural studies on the factor X Friuli variant. Thromb Haemost 1983; 50: 279-284
    PubMedGoogle Scholar
  • 86 Fair DS, Revak DJ, Hubbard JG, Girolami A. Isolation and characterization of the factor X Friuli variant. Blood 1989; 73: 2108-2116
    PubMedGoogle Scholar
  • 87 Kim DJ, Girolami A, James HL. Characterization of recombinant human coagulation factor X Friuli. Thromb Haemost 1996; 75: 313-317
    Article in Thieme ConnectPubMedGoogle Scholar
  • 88 James HL, Girolami A, Fair DS. Molecular defect in coagulation factor X Friuli results from a substitution of serine for proline at position 343. Blood 1991; 77: 317-323
    PubMedGoogle Scholar
  • 89 Rudolph AE, Mullane MP, Porche-Sorbet R, Tsuda S, Miletich JP. Factor X St Louis II. Identification of a glycine substitution at residue 7 and characterization of the recombinant protein. J Biol Chem 1996; 271: 28601-28606
    CrossrefPubMedGoogle Scholar
  • 90 Giannelli F, Green PM, Sommer SS, Poon M-C, Ludwig M, Schwaab R, Reitsma PH, Goossens M, Yoshioka A, Brownlee GG. Haemophilia B (sixth edition): a database of point mutations and short additions and deletions. Nucleic Acids Res 24: 103-118
    PubMedGoogle Scholar
  • 91 Bernardi F, Castaman G, Redaelli R, Pinotti M, Lunghi B, Rodeghiero F, Marchetti G. Topologically equivalent mutations causing dysfunctional coagulation factors VII 294Ala→Val) and X (334Ser→Pro). Hum Molec Genet 1994; 3: 1175-1177
    CrossrefPubMedGoogle Scholar
  • 92 Wallmark A, Larson P, Ljung R, Monroe D, High K. Molecular defect (Gla26-Asp) and its functional consequences in a hereditary factor X deficiency (Factor X Malmo 4). Blood 1991; 78 (Suppl. 01) 60a
    PubMedGoogle Scholar
  • 93 De Stefano V, Leone G, Ferrelli R, Hassan HJ, Macioce G, Bizzi B. Factor X Roma: a congenital factor X variant defective at different degrees in the intrinsic and the extrinsic activation. Brit J Haematol 1988; 69: 387-391
    CrossrefPubMedGoogle Scholar
  • 94 Odom MW, Leone G, De Stefano V, Montiel MM, Boland EJ, Anderson J, Jagadeeswaran P. Five novel point mutations:two causing haemophilia B and three causing factor X deficiency. Molec Cell Probes 1994; 8: 63-65
    CrossrefPubMedGoogle Scholar
  • 95 Kim DJ, Thompson AR, Nash DR, James HL. Factors X Wenatchee I and ILcompound heterozygosity involving two variant proteins. Biochim Biophys Acta 1995; 1271: 327-334
    CrossrefPubMedGoogle Scholar
  • 96 Rao Z, Handford P, Mayhew M, Knott V, Brownlee GG, Stewart D. The structure of a Ca2+-binding epidermal growth factor-like domain:its role in protein-protein interactions. Cell 1995; 82: 131-141
    CrossrefPubMedGoogle Scholar
  • 97 Messier TL, Wong CY, Bovill EG, Long GL, Church WR. Factor X Stockton: a mild bleeding diathesis associated with an active site mutation in factor X. Blood Coag Fibrinol 1996; 7: 5-14
    CrossrefPubMedGoogle Scholar
  • 98 Watzke HH, Lechner K, Roberts HR, Reddy SV, Wesch DJ, Friedman P, Mahr G, Jagadeeswaran P, Monroe DM, High KA. Molecular defect (Gla+14→Lys) and its functional consequences in a hereditary factor X deficiency (Factor X “Vorarlberg”). J Biol Chem 1990; 265: 11982-11989
    PubMedGoogle Scholar
  • 99 Kim DJ, Thompson AR, James HL. Factor X Ketchikan: a variant molecule in which Gly replaces a Gla residue at position 14 in the light chain. Hum Genet 1995; 95: 212-214
    PubMedGoogle Scholar
  • 100 Watzke HH, Wallmark A, Hamaguchi N, Giardina P, Stafford DW, High KA. Factor X Santo Domingo. Evidence that the severe clinical phenotype arises from a mutation blocking secretion. J Clin Invest 1991; 88: 1685-1689
    CrossrefPubMedGoogle Scholar
  • 101 Racchi M, Watzke HH, High KA, Lively MO. Human coagulation factor X deficiency caused by a mutant signal peptide that blocks cleavage by signal peptidase but not targeting and translocation to the endoplasmic reticulum. J Biol Chem 1993; 268: 5735-5740
    PubMedGoogle Scholar
  • 102 Nothwehr SF, Gordon JI. Targeting of proteins into the eukaryotic secretory pathway: signal peptide structure/function relationships. BioEssays 1990; 12: 479-484
    CrossrefPubMedGoogle Scholar
  • 103 Greer J. Comparative modelling methods application to the family of the mammalian serine proteases. Proteins Struct Funct Genet 1990; 7: 317-334
    CrossrefPubMedGoogle Scholar
  • 104 Wallmark A, Ho C, Monroe DM, Tengbom L, High KA. Molecular defect in F.X ‘Öckerӧ’, a mild congenital F.X deficiency. Thromb Haemost 1991; 65: 1263
    PubMedGoogle Scholar
  • 105 Marchetti G, Castaman G, Pinotti M, Lunghi B, Di Iasio MG, Ruggieri M, Rodeghiero F, Bemardi F. Molecular bases of CRM+ factor X deficiency:a frequent mutation (Ser334Pro) in the catalytic domain and substitution (Glul02Lys) in the second EGF-like domain. Brit J Haematol 1995; 90: 910-915
    CrossrefPubMedGoogle Scholar
  • 106 Tuddenham EGD, Cooper DN. The Molecular Genetics of Haemostasis and its Inherited Disorders. Oxford University Press; 1994
    Google Scholar
  • 107 Furie B, Furie BC. Molecular basis of coagulation. Cell 1988; 53: 505-518
    CrossrefPubMedGoogle Scholar
  • 108 Fernlund P, Stenflo J. Beta-hydroxyaspartic acid in vitamin K- dependent proteins. J Biol Chem 1983; 258: 12509-12512
    PubMedGoogle Scholar
  • 109 Nakagawa H, Takahashi N, Fujikawa K, Kawamura Y, lino M, Takeya H, Ogawa H, Suzuki K. Identification of the oligosaccharide structures of human coagulation factor X activation peptide at each glycosylation site. Glycoconjugate J 1995; 12: 173-181
    CrossrefPubMedGoogle Scholar
  • 110 Sinha U, Wolf DL. Carbohydrate residues modulate the activation of coagulation factor X. J Biol Chem 1993; 268: 3048-3051
    CrossrefPubMedGoogle Scholar
  • 111 Bharadwaj D, Harris RJ, Kisiel W, Smith KJ. Enzymatic removal of sialic acid from human factor IX and factor X has no effect on their coagulant activity. J Biol Chem 1995; 270: 6537-6542
    CrossrefPubMedGoogle Scholar
  • 112 Liebman HA, Furie BC, Furie B. The factor IX phospholipid- binding site is required for calcium-dependent activation of factor factor IX by factor XIa. J Biol Chem 1986; 262: 7605-7612
    PubMedGoogle Scholar
  • 113 Morita T, Jackson CM. Preparation and properties of derivatives of bovine factor X and factor Xa from which the ϒ-carboxyglutamic acid domain has been removed. J Biol Chem 1986; 261: 4015-23
    PubMedGoogle Scholar
  • 114 Persson E, Selander M, Linse S, Drakenberg T, Ohlin A-K, Stenflo J. Calcium binding to the isolated β-hydroxyaspartic acid-containing epidermal growth factor-like domain of bovine factor X. J Biol Chem 1989; 264: 16897-1904
    PubMedGoogle Scholar
  • 115 Selander-Sunnerhagen M, Persson E, Dahlqvist I, Drakenberg T, Mayhew M, Robin M, Handford P, Tilley JW, Campbell ID, Brownlee GG. The effect of aspartate hydroxylation on calcium binding to epidermal growth factor-like modules in coagulation factors IX and X. J Biol Chem 1993; 268: 23339-44
    PubMedGoogle Scholar
  • 116 Valcarce C, Holmgren A, Stenflo J. Calcium-dependent interaction between γ-carboxyglutamic acid-containing and N-terminal epidermal growth factor-like modules in factor X. J Biol Chem 269: 26011-26016
    PubMedGoogle Scholar
  • 117 MacGillivray RTA, Fung MR. Molecular biology of factor X. Bailliere’s Clin.Haematol 1989; 2: 897-917
    PubMedGoogle Scholar
  • 118 Bezeaud A, Miyata T, Helley D, Zeng YZ, Kato H, Aillaud MF, Juhan-Vague I, Guillin MC. Functional consequences of the Ser334→Pro mutation in a human factor X variant (factor X Marseille). Eur J Biochem 1995; 234: 140-147
    CrossrefPubMedGoogle Scholar